49 results on '"Andersen, Mads Hald"'
Search Results
2. Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
3. Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
4. Table S2 from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
5. Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
6. Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
7. Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
8. Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
9. Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
10. Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
11. Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
12. Supplementary Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
13. Supplementary Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
14. Table S2 from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
15. Data from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
16. Supplementary Figure S1-S5 from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
17. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
18. Supplementary Figure S1-S5 from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
19. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
20. Data from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
21. Supplementary Figures 1-6 and Supplementary Table 1 from Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
22. Supplementary Methods from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
23. Supplementary Methods from Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
24. Supplementary Figure 1 from HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
25. Supplemental Figures S1-S10 from Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity
26. Data from Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
27. Supplementary Figure 2 from HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
28. Supplemental Figures S1-S10 from Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity
29. Supplementary Figure Legend from HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
30. Supplementary Methods from Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
31. Data from Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
32. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
33. Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
34. MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
35. Abstract 3763: IDO vaccine enhances antigen-specific anti-tumor effects by reducing IDO-expressing antigen presenting cells and MDSCs
36. The Balance Players of the Adaptive Immune System
37. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
38. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
39. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity
40. Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
41. PD-L1 Expression in B-cell Lymphomas and Virus-Associated Malignancies—Letter
42. HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
43. Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
44. CD8 T-Cell Responses Against Cyclin B1
45. CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53
46. The Immunogenicity of the hTERT540-548 Peptide in Cancer
47. The Universal Character of the Tumor-Associated Antigen Survivin
48. The Paradoxical Association between Bcl-2 Expression and Prognosis: Does the Immune System Make the Difference?
49. Immunogenicity of Constitutively Active V599EBRaf
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.